253 related articles for article (PubMed ID: 11735344)
1. Regulated, adenovirus-mediated delivery of tyrosine hydroxylase suppresses growth of estrogen-induced pituitary prolactinomas.
Williams JC; Stone D; Smith-Arica JR; Morris ID; Lowenstein PR; Castro MG
Mol Ther; 2001 Dec; 4(6):593-602. PubMed ID: 11735344
[TBL] [Abstract][Full Text] [Related]
2. [Gene therapy of rat prolactinomas mediated by adenoviral vectors with rat tyrosine hydroxylase gene].
Xu ZQ; Su CB; Chen SS; Ren ZY; Di X; Ma WB
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2003 Apr; 25(2):185-9. PubMed ID: 12905717
[TBL] [Abstract][Full Text] [Related]
3. PTTG expression in different experimental and human prolactinomas in relation to dopaminergic control of lactotropes.
Cristina C; Díaz-Torga GS; Goya RG; Kakar SS; Perez-Millán MI; Passos VQ; Giannella-Neto D; Bronstein MD; Becu-Villalobos D
Mol Cancer; 2007 Jan; 6():4. PubMed ID: 17222350
[TBL] [Abstract][Full Text] [Related]
4. Adenovirus-mediated herpes simplex virus type-1 thymidine kinase gene therapy suppresses oestrogen-induced pituitary prolactinomas.
Windeatt S; Southgate TD; Dewey RA; Bolognani F; Perone MJ; Larregina AT; Maleniak TC; Morris ID; Goya RG; Klatzmann D; Löwenstein PR; Castro MG
J Clin Endocrinol Metab; 2000 Mar; 85(3):1296-305. PubMed ID: 10720079
[TBL] [Abstract][Full Text] [Related]
5. Studies on in vivo gene transfer in pituitary tumors using herpes-derived and adenoviral vectors.
Carri NG; Sosa YE; Brown OA; Albariño C; Romanowski V; Goya RG
Brain Res Bull; 2005 Feb; 65(1):17-22. PubMed ID: 15680541
[TBL] [Abstract][Full Text] [Related]
6. The importance of dopamine in the pathogenesis of experimental prolactinomas.
el-Azouzi M; Hsu DW; Black PM; Jolesz F; Hedley-Whyte ET; Klibanski A; Zervas NT
J Neurosurg; 1990 Feb; 72(2):273-81. PubMed ID: 1967303
[TBL] [Abstract][Full Text] [Related]
7. [Experimental study of dually targeting gene therapy system for pituitary adenomas].
Ma CY; Lu YC; Shi JX; Ren CC; Zhu JD; Gu JR
Zhonghua Yi Xue Za Zhi; 2005 Jan; 85(4):262-6. PubMed ID: 15854489
[TBL] [Abstract][Full Text] [Related]
8. Transfection of human lactotroph adenoma cells with an adenovirus vector expressing tyrosine hydroxylase decreases prolactin release.
Freese A; During MJ; Davidson BL; Gennarelli TA; Kaplitt MG; Flamm ES; Snyder PJ
J Clin Endocrinol Metab; 1996 Jun; 81(6):2401-4. PubMed ID: 8964885
[TBL] [Abstract][Full Text] [Related]
9. HoxD10 gene delivery using adenovirus/adeno-associate hybrid virus inhibits the proliferation and tumorigenicity of GH4 pituitary lactotrope tumor cells.
Cho MA; Yashar P; Kim SK; Noh T; Gillam MP; Lee EJ; Jameson JL
Biochem Biophys Res Commun; 2008 Jul; 371(3):371-4. PubMed ID: 18442473
[TBL] [Abstract][Full Text] [Related]
10. Leukemia inhibitory factor regulates prolactin secretion in prolactinoma and lactotroph cells.
Ben-Shlomo A; Miklovsky I; Ren SG; Yong WH; Heaney AP; Culler MD; Melmed S
J Clin Endocrinol Metab; 2003 Feb; 88(2):858-63. PubMed ID: 12574225
[TBL] [Abstract][Full Text] [Related]
11. Effect of insulin-like growth factor-I gene therapy on the somatotropic axis in experimental prolactinomas.
Cónsole GM; Hereñú CB; Camihort GA; Luna GC; Ferese C; Goya RG
Cells Tissues Organs; 2009; 190(1):20-6. PubMed ID: 18957836
[TBL] [Abstract][Full Text] [Related]
12. Inhibitory effects of antivascular endothelial growth factor strategies in experimental dopamine-resistant prolactinomas.
Luque GM; Perez-Millán MI; Ornstein AM; Cristina C; Becu-Villalobos D
J Pharmacol Exp Ther; 2011 Jun; 337(3):766-74. PubMed ID: 21406548
[TBL] [Abstract][Full Text] [Related]
13. Hyperprolactinemia and prolactinomas.
Mancini T; Casanueva FF; Giustina A
Endocrinol Metab Clin North Am; 2008 Mar; 37(1):67-99, viii. PubMed ID: 18226731
[TBL] [Abstract][Full Text] [Related]
14. Transcriptional targeting to anterior pituitary lactotrophic cells using recombinant adenovirus vectors in vitro and in vivo in normal and estrogen/sulpiride-induced hyperplastic anterior pituitaries.
Southgate TD; Windeatt S; Smith-Arica J; Gerdes CA; Perone MJ; Morris I; Davis JR; Klatzmann D; Löwenstein PR; Castro MG
Endocrinology; 2000 Sep; 141(9):3493-505. PubMed ID: 10965923
[TBL] [Abstract][Full Text] [Related]
15. Diethylstilbestrol-induced prolactinoma: dose-related tumor growth and effect of catecholaminergic cells on prolactin tumor cells.
Palaoğlu S; Sungur A; Cila A; Ozdemir N; Ruacan S
Surg Neurol; 2005; 64 Suppl 2():S42-7. PubMed ID: 16256840
[TBL] [Abstract][Full Text] [Related]
16. Pattern of FGF-2 isoform expression correlated with its biological action in experimental prolactinomas.
Mukdsi JH; De Paul AL; Petiti JP; Gutiérrez S; Aoki A; Torres AI
Acta Neuropathol; 2006 Oct; 112(4):491-501. PubMed ID: 16823503
[TBL] [Abstract][Full Text] [Related]
17. Doxycycline-regulated co-expression of GDNF and TH in PC12 cells.
Wang JJ; Zhang T; Niu DB; Wang K; Li KR; Xue B; Wang XM
Neurosci Lett; 2006 Jun; 401(1-2):142-5. PubMed ID: 16584838
[TBL] [Abstract][Full Text] [Related]
18. Lack of prolactin receptor signaling in mice results in lactotroph proliferation and prolactinomas by dopamine-dependent and -independent mechanisms.
Schuff KG; Hentges ST; Kelly MA; Binart N; Kelly PA; Iuvone PM; Asa SL; Low MJ
J Clin Invest; 2002 Oct; 110(7):973-81. PubMed ID: 12370275
[TBL] [Abstract][Full Text] [Related]
19. Criteria for medical as opposed to surgical treatment of prolactinomas.
Besser M
Acta Endocrinol (Copenh); 1993 Jul; 129 Suppl 1():27-30. PubMed ID: 8103956
[TBL] [Abstract][Full Text] [Related]
20. Inhibitory effect of thalidomide on the growth, secretory function and angiogenesis of estrogen-induced prolactinoma in Fischer 344 rats.
Stepień H; Lawnicka H; Mucha S; Wagrowska-Danilewicz M; Stepień B; Siejka A; Komorowski J
Life Sci; 2006 Sep; 79(18):1741-8. PubMed ID: 16846617
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
